Abbott Laboratories
NYSE:ABT
Abbott Laboratories
NYSE:ABT
Price:
107.32 USD
0.43%
Market Closed
Updated:
Apr 26, 2024
Abbott Laboratories
Income from Continuing Operations
|
Abbott Laboratories
Income from Continuing Operations Peer Comparison
Comparables:
BDX
BSX
EW
SYK
ISRG
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbott Laboratories
NYSE:ABT
|
Income from Continuing Operations
$5.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
13%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Income from Continuing Operations
$1.3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Income from Continuing Operations
$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Income from Continuing Operations
$1.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
14%
|
CAGR 10-Years
14%
|
|
|
Stryker Corp
NYSE:SYK
|
Income from Continuing Operations
$3.2B
|
CAGR 3-Years
26%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Income from Continuing Operations
$2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
See Also
What is Abbott Laboratories's Income from Continuing Operations?
Income from Continuing Operations
5.6B
USD
5.6B
USD
Based on the financial report for Mar 31, 2024, Abbott Laboratories's Income from Continuing Operations amounts to 5.6B USD.
What is Abbott Laboratories's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
13%
13%
Over the last year, the Income from Continuing Operations growth was -3%. The average annual Income from Continuing Operations growth rates for Abbott Laboratories have been -1% over the past three years , 16% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
